A5013557141- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Cancer Risks and Factors
- PARP inhibition in cancer therapy
- Nanoplatforms for cancer theranostics
- Ferroptosis and cancer prognosis
- BRCA gene mutations in cancer
- Global Cancer Incidence and Screening
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Advanced biosensing and bioanalysis techniques
- Cancer-related Molecular Pathways
- Reproductive Biology and Fertility
- DNA Repair Mechanisms
- Gene expression and cancer classification
- Childhood Cancer Survivors' Quality of Life
Duke Cancer Institute
2019-2025
Duke University
2007-2025
Duke Medical Center
2009-2025
Cancer Institute (WIA)
2019-2025
Duke University Hospital
2009-2025
Royal Brisbane and Women's Hospital
2024
University of North Carolina at Chapel Hill
2012-2023
Duke University Health System
2019-2022
UNC Lineberger Comprehensive Cancer Center
2011-2022
Universitätsmedizin Göttingen
2019
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy multiple HER2-targeted agents limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. We randomly assigned patients HER2-positive previously treated trastuzumab, pertuzumab, and trastuzumab emtansine, had or did not brain metastases, to receive either tucatinib placebo, in combination...
Purpose Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined. Patients Methods Clinically annotated, microarray data from 784 early-stage breast cancers were identified, prospectively defined, age-specific cohorts (young: ≤ 45 years, n = 200; older: ≥ 65 211) compared by prognosis, variables, mRNA expression values, single-gene analysis, gene set...
In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) tucatinib. We describe exploratory analyses of intracranial efficacy and participants BMs.Patients were randomly assigned 2:1 to tucatinib or placebo, combination trastuzumab capecitabine. All underwent baseline magnetic resonance imaging; those BMs classified as active stable....
Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 blockade consisting trastuzumab lapatinib added paclitaxel, considering tumor microenvironment molecular features.Patients with stage II III HER2-positive breast cancer underwent biopsy followed by random assignment paclitaxel plus alone (TH) or...
Poly(adenosine diphosphate-ribose) polymerase inhibitor and anti-programmed death receptor-1 monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC).To evaluate the (primary) safety (secondary) of combination treatment niraparib pembrolizumab or metastatic TNBC.This open-label, single-arm, phase 2 study enrolled 55 eligible TNBC irrespective BRCA mutation status programmed death-ligand 1 (PD-L1) expression at 34 US sites. Data were...
Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy HER2-positive brain metastases. Here we report results from additional study cohorts.Patients with measurable, progressive, metastases (92% after receiving surgery and/or radiotherapy) received 240 mg orally once per day plus capecitabine 750 mg/m2 twice 14 days, then 7 days off....
Abstract Purpose: ANG1005, a novel taxane derivative, consists of three paclitaxel molecules covalently linked to Angiopep-2, designed cross the blood–brain and blood–cerebrospinal barriers penetrate malignant cells via LRP1 transport system. Preclinical clinical evidence efficacy with ANG1005 has been previously shown. Patients Methods: A multicenter, open-label phase II study in adult patients measurable recurrent brain metastases from breast cancer (BCBM), or without leptomeningeal...
Abstract Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic breast cancer (MBC). Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA) detection. Experimental Design: Tumor tissue positive for was required eligibility. Neratinib...
Breast cancer metastasis remains a clinical challenge, even within single patient across multiple sites of the disease. Genome-wide comparisons both DNA and gene expression primary tumors metastases in patients could help elucidate underlying mechanisms that cause breast metastasis. To address this issue, we performed exome RNA sequencing matched from 16 patients, totaling 83 distinct specimens. We identified tumor-specific drivers by integrating known protein-protein network information...
The primary objective was to evaluate intracranial response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary hormone receptor-positive (HR+) metastatic breast cancer (MBC). Secondary objectives evaluated extracranial response, pharmacokinetics, tissue exposure, and safety.This nonrandomized, phase II study (NCT02308020) enrolled tumor subtype-specific cohorts A-D: A (HR+, HER2- MBC), B HER2+ C (HR+ MBC LM), D (brain surgical resection)....
It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), which associated poor prognosis. Previous reports the HER2CLIMB trial have demonstrated tucatinib in combination trastuzumab and capecitabine provides survival intracranial benefits for ERBB2-positive MBC BMs.
Abstract The AURORA US Metastasis Project was established with the goal to identify molecular features associated metastasis. We assayed 55 females metastatic breast cancer (51 primary cancers and 102 metastases) by RNA sequencing, tumor/germline DNA exome low-pass whole-genome sequencing global methylation microarrays. Expression subtype changes were observed in ~30% of samples coincident clonality shifts, especially involving HER2. Downregulation estrogen receptor (ER)-mediated cell–cell...
The ability to predict metastatic potential could be of great clinical importance, however, it is uncertain if predicting metastasis specific vital organs feasible. As a first step in evaluating predictions, we analyzed multiple primary tumors and pairs determined that >90% 298 gene expression signatures were found similarly expressed between matched metastases; therefore, may good predictor propensity. Next, using dataset >1,000 human breast tumor microarrays HER2-enriched subtype...